On September 24, 2024, our 0.3 mL specification of Procaterol Hydrochloride Inhalation Solution received production approval from the National Medical Products Administration (NMPA), alongside the 0.5 mL specification. Both specifications were approved for pediatric indications. Procaterol H

  On December 13, 2023, the List of Drugs Covered by China’s Basic Medical Insurance, Work-related Injury Insurance and Childbirth Insurance (2023) (hereafter referred to as “China’s National Reimbursement Drug List”) was unveiled by China’s National Healthcare Se

  On October 23, 2023, our company's product, Moxifloxacin Hydrochloride Eye Drops, received approval for market launch with the registration number of H20234318 issued by the NMPA.   Moxifloxacin Hydrochloride is an efficient and broad-spectrum antibacterial drug widely used in the tre

  On June 30, 2023, our product Procaterol Hydrochloride Inhalation Solution was approved for marketing (approval No.: H20233837), making it the first of this kind to be launched domestically.   Procaterol hydrochloride is a β2 agonist with high selectivity for β2 adrenergic r

  At 16:00 pm on May 18, 2023, the warehouse completed the delivery of the first order of Dingda-Salbutamol Sulfate Inhalation Solution (2.5 mL: 5 mg) manufactured by Nanjing Aureole Pharmaceutical Co., Ltd. Aureole Pharmaceutical people finally ushered in the official sale of the product afte

  We have focused on inhalation product R&D, and the results are prominent! Following the approval of the first product at the end of March, our second product, Terbutaline Sulfate Nebulizer Inhalation Solution with two strengths, was approved for marketing on April 14, with the approval n

  On March 24, 2023, we successfully obtained the manufacturing approvals for Salbutamol Sulfate Inhalation Solution with two strengths, with the approval numbers of Guo. Yao. Zhun. Zi. No. H20233355, and Guo. Yao. Zhun. Zi. No. H20233356 respectively, which are deemed to have passed the consi

  In December 2022, our Company passed the evaluation of “Jiangbei New Area Health Enterprise” and was selected as “Jiangbei New Area Health Enterprise”.   Health is an inevitable requirement for the overall development of human beings, a basic condition for econ

  Our Company was recognized as “Innovation Company” in the third list in 2022.   The recognization of “Innovation Company” has strict requirements on product areas, patent achievements, R&D investment, growth indicators and talent structure. We started to pr

          The Salbutamol Sulfate Inhalation Solution (2.5ml:2.5mg ) and the Salbutamol Sulfate Inhalation Solution (2.5ml:5mg ), which researched and developed independently by Aureole and is the first product to register, receives the reference number issued by CDE on Nov